[go: up one dir, main page]

MX2018002047A - Uso de ureidomustina (bo-1055) en el tratamiento del cancer. - Google Patents

Uso de ureidomustina (bo-1055) en el tratamiento del cancer.

Info

Publication number
MX2018002047A
MX2018002047A MX2018002047A MX2018002047A MX2018002047A MX 2018002047 A MX2018002047 A MX 2018002047A MX 2018002047 A MX2018002047 A MX 2018002047A MX 2018002047 A MX2018002047 A MX 2018002047A MX 2018002047 A MX2018002047 A MX 2018002047A
Authority
MX
Mexico
Prior art keywords
ureidomustine
cancer treatment
leukemia
acute
cancer
Prior art date
Application number
MX2018002047A
Other languages
English (en)
Inventor
Moore Malcolm
Hung Shieh Jae-
Long SU Tsann-
Chang Lee Te-
Original Assignee
Academia Sinica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academia Sinica filed Critical Academia Sinica
Publication of MX2018002047A publication Critical patent/MX2018002047A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un método de uso de ureidomustina (BO-1055), un agente de reticulación de ADN soluble en agua, en el tratamiento de un cáncer, seleccionado del grupo que consiste en varios tipos de leucemia humana [como la leucemia mieloide aguda (ALL) y Leucemia linfoblástica aguda B (B-ALL)], linfomas, carcinoma de pulmón de células pequeñas (SCLC), sarcomas y otros.
MX2018002047A 2015-08-17 2016-08-17 Uso de ureidomustina (bo-1055) en el tratamiento del cancer. MX2018002047A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562206081P 2015-08-17 2015-08-17
PCT/US2016/047264 WO2017031156A1 (en) 2015-08-17 2016-08-17 Use of ureidomustine (bo-1055) in cancer treatment

Publications (1)

Publication Number Publication Date
MX2018002047A true MX2018002047A (es) 2018-09-18

Family

ID=58051562

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002047A MX2018002047A (es) 2015-08-17 2016-08-17 Uso de ureidomustina (bo-1055) en el tratamiento del cancer.

Country Status (12)

Country Link
US (2) US10548861B2 (es)
EP (1) EP3337784A4 (es)
JP (1) JP2018535186A (es)
KR (1) KR20180052617A (es)
CN (1) CN107922321A (es)
AU (1) AU2016308116A1 (es)
BR (1) BR112018003191A2 (es)
CA (1) CA2994009A1 (es)
MX (1) MX2018002047A (es)
SG (1) SG10202001388YA (es)
TW (1) TWI644667B (es)
WO (1) WO2017031156A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210355501A1 (en) * 2018-09-24 2021-11-18 Albert Einstein College Of Medicine Interleukin-8 for maintenance of human acute myeloid leukemia and myelodysplastic syndrome and uses thereof
CN109609434B (zh) * 2018-11-23 2022-08-30 湖南中医药大学 生物转化合成天麻素的方法及应用
CN109765370B (zh) * 2018-12-17 2021-11-23 杭州京北生物科技有限公司 一种前列腺癌诊断试剂盒及制备方法与应用
KR102246582B1 (ko) * 2019-04-03 2021-04-30 이화여자대학교 산학협력단 올리고펩타이드를 이용한 줄기세포의 연골세포로의 분화 유도 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9193687B2 (en) * 2007-01-11 2015-11-24 Academia Sinica Phenyl N-mustard linked to DNA-affinic molecules or water-soluble aryl rings, method and their use as cancer therapeutic agents
US8222297B2 (en) * 2007-01-11 2012-07-17 Academia Sinica Aniline or phenol mustards linked to DNA-affinic molecules or water-soluble aromatic rings and their use as cancer therapeutic agents

Also Published As

Publication number Publication date
WO2017031156A8 (en) 2018-04-26
CA2994009A1 (en) 2017-02-23
WO2017031156A1 (en) 2017-02-23
JP2018535186A (ja) 2018-11-29
US20200246284A1 (en) 2020-08-06
KR20180052617A (ko) 2018-05-18
SG10202001388YA (en) 2020-04-29
EP3337784A1 (en) 2018-06-27
BR112018003191A2 (pt) 2018-12-04
EP3337784A4 (en) 2019-04-17
TW201711679A (zh) 2017-04-01
TWI644667B (zh) 2018-12-21
AU2016308116A1 (en) 2018-02-15
US10548861B2 (en) 2020-02-04
US20190008808A1 (en) 2019-01-10
CN107922321A (zh) 2018-04-17

Similar Documents

Publication Publication Date Title
IL275055A (en) Tertiary antibody, method for its preparation and use
MX393936B (es) Combinacion de elafibranor o derivados del mismo con un agente anti-ehna, antifibrotico o anticolestasico
MY187540A (en) Compounds active towards bromodomains
EP4389227A3 (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
LT3362065T (lt) Kompleksinė terapija, apimanti ivosidenibą, citarabiną ir daunorubiciną arba idarubiciną, skirta ūminės mielogeninės leukemijos gydymui
PH12016500270A1 (en) Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases
SG11202008132UA (en) Composition, method and use
ZA202204657B (en) Compounds, compositions, and methods for treating t-cell acute lymphoblastic leukemia
SA519410259B1 (ar) مركب كبير الحلقات واستخداماته
AU2015267099A8 (en) Use of eribulin in the treatment of cancer
IL289096A (en) Parenteral lysophosphatidylcholine formulations such as lpc-epa, lpc-dha and their use in treatment
MX2024003228A (es) Compuestos de union al receptor de la hormona antimulleriana tipo ii (amhrii) para prevenir o tratar canceres de pulmon.
MX2018002047A (es) Uso de ureidomustina (bo-1055) en el tratamiento del cancer.
SG11201912228WA (en) Agents, uses and methods for treatment
ZA202007187B (en) Solubilized apyrases, methods and use
SG11201913302SA (en) Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc, sclc and other cancers
ZA202204075B (en) Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof
TW201713323A (en) Therapeutic compositions and methods of use thereof
CA3011003A1 (en) Bacterial ghosts for the treatment of cancer
MX2019002947A (es) Combinaciones que incluyen abx196 para el tratamiento de cancer.
MX2019002901A (es) Tratamiento de esclerosis multiple con chs-131.
PH12021551138A1 (en) Application of chidamide in combination with r-chop, and drug combination
GB201910299D0 (en) Medical uses, methods and uses
GB201907832D0 (en) Medical uses, methods and uses
GB2587109B (en) Demethylation method, and demethylation apparatus and cancer therapy apparatus comprising same